Latest updates in treatment for the field of HER2-positive breast cancer

Share :
Published: 8 Jul 2022
Views: 106
Dr Delia Guaqueta - Memorial Healthcare System, Hollywood, USA

Dr Delia Guaqueta speaks to ecancer at the ASCO Direct Highlights 2022 Miami Symposium about some of the latest updates in treatment for the field of HER2-positive breast cancer.

Firstly, she discusses the promising results of the HER2CLIMB study with the use of tucatinib benefiting patients - even showing activity in those with brain metastases.

Dr Guaqueta then details the DESTINY-Breast03 study, which evaluates the use of trastuzumab deruxtecan for metastatic HER2-positive breast cancer, with the treatment improving progression-free survival in patients.